Page 5 of 19

PA30.2 | Carcinoma of the Breast — SDL Guide

Learning Objectives

Classify carcinoma of the breast into in situ (DCIS, LCIS) and invasive categories with their subtypes.
Describe the epidemiology, hormonal risk factors, and hereditary predisposition (BRCA1/2) for breast cancer.
Explain the molecular pathogenesis: ER signalling pathway, HER2 amplification, and the ductal carcinogenesis sequence.
Compare the gross and microscopic features of the common invasive carcinoma subtypes (IDC NST, ILC, medullary, mucinous, tubular, inflammatory, Paget disease).
Classify breast carcinoma by molecular/intrinsic subtype (Luminal A/B, HER2-enriched, basal-like/triple-negative) and relate this to ER/PR/HER2 immunohistochemistry.
Apply the Nottingham (Bloom-Richardson) grading system and TNM staging to a breast carcinoma case.
List the prognostic and predictive factors and describe the routes of spread of breast carcinoma.

INSTRUCTIONS

Breast carcinoma is the most common cancer in women worldwide and a top cause of cancer death in Indian women. Understanding its classification and molecular biology is essential not only for the pathology examination but for appreciating how modern oncologists choose surgery, chemotherapy, hormonal therapy, and targeted agents. Work through each block sequentially; use the micro-quizzes to self-test before moving on.

References

Robbins & Cotran Pathologic Basis of Disease, 10th ed., Ch. 23 — The Breast (textbook)
Harsh Mohan: Textbook of Pathology, 8th ed., Ch. 27 — Diseases of the Breast (textbook)
Kumar, Abbas & Aster: Robbins Basic Pathology, 10th ed., Ch. 22 (textbook)
WHO Classification of Tumours of the Breast, 5th ed., 2022 (guideline)

Version 2.0 | NMC CBUC 2024

CLINICAL SCENARIO

A 48-year-old woman notices a hard, painless lump in her right breast upper outer quadrant. Fine-needle aspiration shows clusters of pleomorphic cells with irregular nuclei. Her mother had breast cancer at 52. Immunohistochemistry of the core biopsy returns: ER+, PR+, HER2 2+ (equivocal), Ki-67 18%. Her oncologist orders a FISH test and recommends a multidisciplinary tumour board review.

By the end of this module, you will understand exactly why each of those IHC markers was ordered, what the results mean for prognosis, and how the microscopic features you study today translate directly into the treatment decision for this patient.

WHY THIS MATTERS

Breast carcinoma is the most common invasive cancer in women globally, accounting for ~2.3 million new cases per year (WHO 2022). In India it has overtaken cervical cancer as the leading female malignancy. For Year-2 MBBS, this topic appears in every university theory and practical examination. More importantly, pathologists issue every diagnosis that drives surgery, chemotherapy, and targeted therapy — understanding the morphology and molecular subtypes makes you an effective partner in the multidisciplinary team from day one of clinical posting.

RECALL

Before starting, test your recall:

Name the two main in situ breast lesions you should know.
Which chromosome carries BRCA1? Which carries BRCA2?
What does the term desmoplasia mean histologically?
What are the three parameters in the Nottingham grading system?
Which lymph node group is most important in breast cancer staging?

If any of these are unfamiliar, that is fine — each will be covered in detail. Use them as a roadmap for what to watch for.

Epidemiology and Risk Factors

Breast carcinoma has a bimodal age distribution: a small pre-menopausal peak and a larger post-menopausal peak; the median age at diagnosis in India is ~50–52 years, roughly a decade earlier than in Western populations.

Three-panel diagram: Panel A shows a bimodal age-incidence curve for female breast carcinoma with labeled pre-menopausal (~40s) and post-menopausal (~60s) peaks and a lifetime risk annotation of ~12%; Panel B lists key risk factors grouped into hormonal, hereditary, and proliferative disease categories; Panel C compares BRCA1 and BRCA2 genes across chromosome location, lifetime risk, tumour type, and associated cancers. — **Panel A:** Bimodal age-incidence curve with pre-menopausal peak (~40s), post-menopausal peak (~60s), menopause reference line at ~50 years, and lifetime risk bracket (~12% Western women). **Panel B:** Three colour-coded risk factor groups: (1) Hormonal/Estrogen Exposure — menarche, menopause, parity, HRT, obesity; (2) Hereditary Predisposition — family history, BRCA1/2, TP53/PTEN/CDH1; (3) Proliferative Breast Disease with Atypia — ADH 4–5×, ALH 4–5× bilateral, usual hyperplasia no risk. **Panel C:** BRCA1 vs BRCA2 comparison table — chromosome locus, lifetime breast cancer risk percentage, predominant tumour subtype, male breast cancer association, and other cancer risks (ovarian, pancreatic).

Risk factors can be organised into three broad categories:

1. Hormonal/Estrogen Exposure
• Early menarche (<12 yrs) and late menopause (>55 yrs) — prolonged estrogen exposure
• Nulliparity or first pregnancy after age 30
• Prolonged combined HRT or oral contraceptive use
• Obesity (post-menopausal: adipose tissue aromatises androgens → estrogen)
• Exogenous estrogen (DES exposure in utero — rare)

2. Hereditary Predisposition
• First-degree relative with breast cancer → 1.5–2× risk; 2 relatives → 2–4×
• BRCA1 (chromosome 17q21) — predominantly triple-negative / basal-like carcinomas; lifetime risk 50–80%
• BRCA2 (chromosome 13q12–13) — more often ER-positive carcinomas; lifetime risk 40–70%; also associated with male breast cancer
• Other high-risk genes: TP53 (Li-Fraumeni), PTEN (Cowden syndrome), CDH1 (hereditary lobular carcinoma)

3. Proliferative Breast Disease with Atypia
• Usual ductal hyperplasia — no increased risk
• Sclerosing adenosis — slight risk
• Atypical ductal hyperplasia (ADH) — 4–5× increased risk
• Atypical lobular hyperplasia (ALH) — 4–5× increased risk (risk is bilateral)

Other factors: ionising radiation (especially in adolescence — e.g. mantle field radiation for Hodgkin lymphoma), high breast density on mammography, and contralateral breast cancer all increase risk.

Pathogenesis: Molecular Pathways

Three major molecular mechanisms underlie the development of breast carcinoma.

Three-panel schematic comparing breast carcinoma pathogenesis: Panel A shows estrogen binding ER-alpha driving cyclin D1/c-MYC/IGF-1R upregulation leading to ER-positive luminal carcinoma; Panel B shows HER2 gene amplification activating RAS-MAPK and PI3K-AKT-mTOR cascades leading to aggressive HER2-positive carcinoma; Panel C shows BRCA1/2 loss causing defective homologous recombination and genomic instability leading to triple-negative carcinoma. — **Panel A:** Estrogen (E2); ER-alpha nuclear receptor; Estrogen Response Element (ERE); Cyclin D1, c-MYC, IGF-1R (downstream effectors); ER+/PR+ Luminal Carcinoma outcome; tamoxifen/aromatase inhibitor sensitivity note. **Panel B:** Chr 17q12 HER2 gene amplification; HER2 homodimer/heterodimer RTK; RAS-RAF-MEK-ERK (MAPK branch); PI3K-AKT-mTOR branch; proliferation/anti-apoptosis/angiogenesis effectors; HER2+ Carcinoma outcome; trastuzumab sensitivity note. **Panel C:** BRCA1/2 tumour suppressor gene; germline mutation + somatic LOH; defective homologous recombination; genomic instability / DSB accumulation; Triple-Negative Carcinoma (ER−/PR−/HER2−) outcome; PARP inhibitor sensitivity note.

1. Estrogen Receptor (ER) Pathway — Luminal Carcinomas

Estrogen binds nuclear ER-alpha → receptor-ligand complex translocates to nucleus → binds estrogen response elements → upregulates cyclin D1, c-MYC, IGF-1R → cell proliferation and survival. Prolonged ER stimulation accumulates mutations in ductal epithelium. These tumours are ER+/PR+, low to moderate grade, and respond to hormonal therapy (tamoxifen, aromatase inhibitors).

2. HER2 (ERBB2) Amplification Pathway

HER2 (chromosome 17q12) encodes a receptor tyrosine kinase. Amplification (not just overexpression) occurs in ~15–20% of breast carcinomas. The activated HER2 homodimer/heterodimer drives RAS-MAPK and PI3K-AKT-mTOR signalling → uncontrolled proliferation, anti-apoptosis, angiogenesis. These tumours are high-grade, aggressive, and sensitive to trastuzumab (Herceptin) — an anti-HER2 monoclonal antibody.

3. BRCA1/2 Pathway — Hereditary & Triple-Negative Carcinomas

BRCA1/2 are tumour suppressor genes encoding proteins critical for homologous recombination DNA repair. Loss of both alleles (germline mutation + somatic LOH) causes genomic instability. BRCA1-related tumours are typically high-grade, ER/PR/HER2-negative (triple-negative), basal-like; BRCA2 tumours are more often ER-positive. These tumours cannot repair double-strand DNA breaks and are exquisitely sensitive to PARP inhibitors (e.g. olaparib).

The Ductal Carcinogenesis Sequence:

Normal ductal epithelium → usual ductal hyperplasia (UDH) → atypical ductal hyperplasia (ADH) → ductal carcinoma in situ (DCIS) → invasive ductal carcinoma. Each step accumulates molecular alterations: ER expression, HER2 amplification, TP53 mutation, and loss of CDKN2A (p16). This sequence takes 10–15 years on average.

CLINICAL PEARL

BRCA testing and surgical decision-making: When a premenopausal woman is diagnosed with triple-negative breast cancer, BRCA1/2 germline testing is reflexively offered. A confirmed BRCA1 mutation changes the surgical plan (risk-reducing contralateral mastectomy), guides surveillance (ovarian cancer risk), and opens eligibility for PARP inhibitors. The pathologist's role begins with accurate hormone receptor and HER2 reporting — that single IHC report can dictate whether a patient undergoes additional genetic testing.

Ductal Carcinoma In Situ (DCIS)

Ductal carcinoma in situ (DCIS) is a malignant proliferation of ductal epithelial cells confined within the basement membrane — there is no invasion of the surrounding stroma. It is detectable by mammography (often as clustered microcalcifications) and represents ~15–25% of screen-detected breast cancers.

Six-panel H&E histology diagram: Panel A shows an annotated low-power cross-section of a DCIS-distended duct with labeled ductal lumen, malignant cells, intact myoepithelium, basement membrane, and stroma; Panels B–F illustrate the five DCIS architectural subtypes (Comedo, Cribriform, Micropapillary, Papillary, Solid) with grade badges. — **Panel A:** Ductal lumen (central), malignant epithelial cells (crowded, pleomorphic nuclei), myoepithelial layer (intact, flattened, peripheral), basement membrane (intact eosinophilic rim), fibrous stroma (surrounding); scale bar 200 µm. **Panel B:** Comedo pattern — central necrosis with ghost cells and dystrophic calcification; grade badge: High Grade (red). **Panel C:** Cribriform pattern — rigid sieve-like rounded spaces within solid cell sheets; grade badge: Low–Int (amber). **Panel D:** Micropapillary pattern — intraluminal epithelial tufts with bulbous tips, no fibrovascular cores; grade badge: Low–Int (amber). **Panel E:** Papillary pattern — true papillary fronds with thin fibrovascular cores; grade badge: Low (green). **Panel F:** Solid pattern — duct completely filled by uniform malignant cells with no special internal architecture; grade badge: Variable (grey).

Classification by Architecture and Grade:

Pattern	Key Feature	Grade
Comedo	Central necrosis (ghost cells) → calcifies → linear/branching microcalcs on mammogram	High
Cribriform	Regular rounded spaces (sieve-like) within solid cell sheets	Low–intermediate
Micropapillary	Intra-luminal papillary tufts without fibrovascular cores	Low–intermediate
Papillary	Papillary fronds with fibrovascular cores; often in elderly women	Low
Solid	Completely fills lumen with no special pattern	Variable

Comedo DCIS is the most clinically important subtype:
• Central coagulative necrosis of high-grade cells that calcify → linear/branching microcalcifications on mammography
• High nuclear grade, prominent mitoses, HER2 amplification common
• Highest risk of progression to invasive carcinoma (~30–50% if untreated)

Side-by-side medium-power histology diagram comparing comedo DCIS (left, showing central necrosis with ghost cells and calcification) and cribriform DCIS (right, showing regular punched-out fenestrations in a solid tumor sheet), with both ducts labeled to show preserved myoepithelial layer. — **Panel A:** Comedo DCIS: central necrosis zone (pink amorphous debris), ghost cells (pale nucleus-free outlines), dystrophic calcification (purple deposits), solid viable tumor cells with pleomorphic nuclei, preserved myoepithelial cell layer (green-highlighted rim). **Panel B:** Cribriform DCIS: regular round-to-oval fenestrations (sieve/Roman-arch pattern), polarized luminal cells lining fenestration borders, solid tumor sheet without necrosis, preserved myoepithelial cell layer (green-highlighted rim). **Bottom bar:** IHC key: myoepithelial markers p63, calponin, SMMHC — positive in DCIS (in situ); absent = invasion.

Key distinction: In DCIS, the myoepithelial cell layer is preserved (demonstrable by IHC with p63, calponin, or smooth muscle myosin heavy chain). Loss of myoepithelium = invasion. This is the critical distinguishing feature between in situ and invasive carcinoma in daily diagnostic practice.